Psychopharmacological evidence for increase in receptor sensitivity following chronic morphine treatment.
D000109:Acetylcholine / Q000378:metabolism; D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D001285:Atropine / Q000494:pharmacology; D001522:Behavior, Animal / Q000187:drug effects*; D001921:Brain / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism; D004361:Drug Tolerance; D008297:Male; D009020:Morphine / Q000494:pharmacology*; D009388:Neostigmine / Q000494:pharmacology; D018377:Neurotransmitter Agents / Q000378:metabolism; D009538:Nicotine / Q000494:pharmacology; D009638:Norepinephrine / Q000378:metabolism; D010830:Physostigmine / Q000494:pharmacology; D010862:Pilocarpine / Q000494:pharmacology; D051381:Rats; D011941:Receptors, Adrenergic / Q000187:drug effects; D011950:Receptors, Cholinergic / Q000187:drug effects; D011955:Receptors, Drug / Q000187:drug effects*; D012054:Reinforcement, Psychology; D013268:Stimulation, Chemical; D013997:Time Factors
D000316:Adrenergic alpha-Agonists; D000317:Adrenergic alpha-Antagonists; D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D018377:Neurotransmitter Agents; D011941:Receptors, Adrenergic; D011950:Receptors, Cholinergic; D011955:Receptors, Drug; D010862:Pilocarpine; D009388:Neostigmine; D009538:Nicotine; D009020:Morphine; D001285:Atropine; D010830:Physostigmine; D000109:Acetylcholine; D004298:Dopamine; D009638:Norepinephrine